A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Akeso610 enrolled

Overview

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

Study Type

OBSERVATIONAL

Enrollment

610

Conditions

Locally Advanced Unresectable or Metastatic Gastric Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed. 2. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial. 3. Agree to proceed with the extended follow-up procedures. 4. This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time. Exclusion Criteria: * None

Locations (1)

Peking University Cancer Hospital

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

Overall Survival (OS)

OS is defined as the time from randomization to death due to any cause.

Time frame: Up to approximately 5 years

Central Contacts

Zhifang Yao，MD

CONTACT

86-0760-89873999 clinicaltrials@akesobio.com

Jiafu Ji, MD

CONTACT

jijiafu@hsc.pku.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.